

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 May 2023 (04.05.2023)



(10) International Publication Number
WO 2023/076989 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) A61K 47/68 (2017.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/US2022/078767

(22) International Filing Date:
27 October 2022 (27.10.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/273,411 29 October 2021 (29.10.2021) US

(71) Applicant: SEAGEN INC. [US/US]; 21823 30th Drive SE, Bothell, Washington 98021 (US).

(72) Inventors: HEISER, Ryan; 21823 30th Drive SE, Bothell, Washington 98021 (US). KNOWLES, Scott; 21823 30th Drive SE, Bothell, Washington 98021 (US). PUHLMANN, Markus; 21823 30th Drive SE, Bothell, Washington 98021 (US).

(74) Agent: BANKO, Max et al.; Seagen Inc., 21823 30th Drive SE, Bothell, Washington 98021 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,

(54) Title: METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-CD30 ANTIBODY-DRUG CONJUGATE

FIG. 4C

Change in CD30 expression on DTC Tcells
with α PD1 Treatment



(57) Abstract: The invention provides an anti-PD-1 antibody and an antibody-drug conjugate that binds to CD30 and their use in methods of treating solid tumors. The invention also provides compositions and kits comprising the anti-PD-1 antibody and the antibody-drug conjugate that binds to CD30 for use in treating solid tumors.

[Continued on next page]

SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*